TBPH Q4 2016 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$697M

Q4 2016 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M+46.2% YoY

Gross Profit

$5M79.9% margin

Operating Income

-$58M-1016.1% margin

Net Income

-$67M-1182.9% margin

EPS (Diluted)

$-1.36

QoQ Revenue Growth

-70.2%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$29M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$639M

Total Liabilities

$289M

Stockholders' Equity

$350M

Cash & Equivalents

$345M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$4M	+46.2%
Gross Profit	$5M	$692,000	+556.9%
Operating Income	-$58M	-$56M	-3.7%
Net Income	-$67M	-$45M	-50.2%